Zimmer Biomet (NYSE:ZBH) had its price target boosted by UBS Group from $158.00 to $165.00 in a report issued on Wednesday morning, Stock Target Advisor reports. UBS Group currently has a buy rating on the medical equipment provider’s stock.

Other research analysts have also recently issued reports about the stock. Cowen set a $140.00 price objective on shares of Zimmer Biomet and gave the stock a buy rating in a research note on Monday, September 23rd. ValuEngine cut shares of Zimmer Biomet from a buy rating to a hold rating in a research note on Wednesday, August 21st. Jefferies Financial Group raised their price objective on shares of Zimmer Biomet from $150.00 to $167.00 and gave the stock a buy rating in a research note on Monday, July 29th. They noted that the move was a valuation call. Argus raised shares of Zimmer Biomet from a hold rating to a buy rating and set a $160.00 price objective for the company in a research note on Monday, August 12th. Finally, Stifel Nicolaus set a $155.00 price objective on shares of Zimmer Biomet and gave the stock a buy rating in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $147.95.

ZBH stock opened at $144.00 on Wednesday. The company has a current ratio of 1.19, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. The firm has a 50 day moving average of $137.06 and a 200-day moving average of $128.64. Zimmer Biomet has a 12-month low of $96.99 and a 12-month high of $144.96. The company has a market cap of $28.81 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 2.66 and a beta of 1.14.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $1.77 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.75 by $0.02. Zimmer Biomet had a negative net margin of 1.14% and a positive return on equity of 13.89%. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same period last year, the company posted $1.63 EPS. The company’s revenue was up 3.0% on a year-over-year basis. Sell-side analysts forecast that Zimmer Biomet will post 7.83 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.67%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.57%.

In other Zimmer Biomet news, VP Chad F. Phipps sold 7,000 shares of Zimmer Biomet stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $138.28, for a total value of $967,960.00. Following the transaction, the vice president now owns 37,722 shares in the company, valued at approximately $5,216,198.16. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Chad F. Phipps sold 32,800 shares of Zimmer Biomet stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $140.00, for a total transaction of $4,592,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,244 shares of company stock worth $5,621,885. 0.72% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Zimmer Biomet by 1.0% during the 2nd quarter. Vanguard Group Inc. now owns 15,453,961 shares of the medical equipment provider’s stock valued at $1,819,550,000 after acquiring an additional 145,726 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Zimmer Biomet by 45.5% during the 2nd quarter. Invesco Ltd. now owns 7,079,312 shares of the medical equipment provider’s stock valued at $833,519,000 after acquiring an additional 2,213,085 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Zimmer Biomet by 3.0% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,054,204 shares of the medical equipment provider’s stock valued at $712,822,000 after acquiring an additional 177,006 shares in the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Zimmer Biomet by 3,725.2% during the 2nd quarter. Nuveen Asset Management LLC now owns 4,258,315 shares of the medical equipment provider’s stock valued at $501,374,000 after acquiring an additional 4,146,991 shares in the last quarter. Finally, Boston Partners lifted its holdings in shares of Zimmer Biomet by 120.2% during the 2nd quarter. Boston Partners now owns 3,863,068 shares of the medical equipment provider’s stock valued at $454,952,000 after acquiring an additional 2,108,589 shares in the last quarter. Institutional investors and hedge funds own 87.72% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Story: Earnings Reports

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.